Simulations Plus Enters Agreement with Distributor in China
February 02 2021 - 8:30AM
Business Wire
Extends reach of MonolixSuite™ to China’s
growing pharmacology market
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of
modeling and simulation solutions for the pharmaceutical,
biotechnology, chemical, and consumer goods industries, today
announced that it has entered into a distribution agreement with
Mosim, one of China’s leading biopharmaceutical services companies,
to distribute MonolixSuite™, the Lixoft division’s
pharmacokinetic/pharmacodynamic (PK/PD) modeling platform, in
China.
Founded in 2015, Mosim was the first clinical contract research
organization (CRO) providing clinical pharmacology services in
China. During the last 5 years, by expanding its clinical operation
team with a focus on clinical pharmacology studies, Mosim has
become a full service clinical CRO. With a staff of over 100
qualified scientists, Mosim will provide extensive connections
throughout industry, academia, and regulatory agencies to increase
awareness of MonolixSuite, including PKanalix, Monolix, and
Simulx.
Jiansong Yang, chief executive officer of Mosim, said: “We are
excited to be partnering with Lixoft, whose MonolixSuite is the
most advanced and simple solution for non-linear mixed effects
modeling (NLME) for pharmacometrics. In recent years, we’ve seen an
increasing demand for model-informed drug development by China’s
pharmaceutical industry as well as its regulatory agency, the
National Medical Products Administration, or NMPA (formerly known
as the China Food and Drug Administration). Working with Lixoft
will allow us to provide China’s pharmaceutical scientists with a
powerful tool for population PK/PD modeling. Also, as a leading
provider of modeling and simulation in China, Mosim is committed to
training young clinical pharmacologists and pharmacometricians, and
MonolixSuite will contribute significantly to this important
work.”
“China is one of the fastest growing markets in pharmaceutical
research and development with the emergence of domestic companies
for the development of new drugs,” added Jonathan Chauvin,
president of Lixoft. “In 2019, we hosted MonolixSuite modeling and
simulation workshops at Innovent Biologics and the International
Symposium of Quantitative Pharmacology (ISQP) in China, and the
response to our technology was very enthusiastic. There are now
approximately one hundred users in China utilizing our products in
their drug development efforts, so we are confident that this new
partnership with Mosim is perfectly timed to serve the growing
needs of China’s scientific community.”
The MonolixSuite is a unique solution for non-compartmental
analysis (NCA), PK/PD and population modeling for Clinical
Pharmacology and Pharmacometrics that supports the efforts of
pharmacometricians to manage their projects from the first data
exploration up to clinical trial simulations. With a powerful,
unified, and user-friendly interface, the MonolixSuite consists of
three applications: PKanalix for non-compartmental and
compartmental analysis, Monolix for population modeling and
diagnostics, and Simulx for clinical trial simulations. These
integrated and interactive applications are based on the most
state-of-the-art and rigorous statistical methods in order to
deliver reliable and high-quality results on a timely basis.
This distribution agreement with Mosim for MonolixSuite will
complement the existing arrangement between Simulations Plus and
PharmoGo Co., Limited, the China-based distributor for the
Company’s software products, including GastroPlus® and ADMET
Predictor®, thereby expanding the Company’s reach across discovery,
pre-clinical and clinical research and development within China’s
pharmaceutical industry.
About Simulations Plus, Inc.
Simulations Plus, Inc., is a leading provider of modeling and
simulation software and consulting services supporting drug
discovery, development research, and regulatory submissions. With
our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer
solutions which bridge machine learning, physiologically based
pharmacokinetics, quantitative systems pharmacology/toxicology, and
population PK/PD modeling approaches. Our technology is licensed
and applied by major pharmaceutical, biotechnology, chemical,
consumer goods companies and regulatory agencies worldwide. For
more information, visit our website at
www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
and filed with the U.S. Securities and Exchange Commission.
Follow us on Twitter | LinkedIn | YouTube
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210202005463/en/
Simulations Plus Investor Relations
Ms. Renee Bouche 661-723-7723 renee@simulations-plus.com
Hayden IR Mr. Cameron Donahue
651-653-1854 slp@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Sep 2023 to Sep 2024